Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02552888
Other study ID # TulaneU
Secondary ID 1U54GM104940
Status Completed
Phase Phase 2
First received
Last updated
Start date March 2016
Est. completion date June 2017

Study information

Verified date March 2021
Source Tulane University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The proposed randomized controlled trial will test the safety and efficacy of combination therapy with sodium nitrite and isoquercetin on endothelial function and inflammation among patients with chronic kidney disease.


Description:

The proposed randomized controlled trial will test the safety and efficacy of combination therapy with sodium nitrite and isoquercetin on endothelial function and inflammation among patients with chronic kidney disease. Investigators will recruit 70 albuminuric CKD patients and randomly assign participants to combination therapy with sodium nitrite and isoquercetin or placebo for three months.


Recruitment information / eligibility

Status Completed
Enrollment 70
Est. completion date June 2017
Est. primary completion date June 2017
Accepts healthy volunteers No
Gender All
Age group 21 Years to 74 Years
Eligibility Inclusion Criteria: - Men and women aged 21-74 years old with any race/ethnicity background - CKD as defined by an eGFR <60 ml/min/1.73 m2 or urinary albumin to creatinine ratio = 30 mg/g or protein to creatinine ratio =150 mg/g. - Systolic BP=120 and <180 mmHg and/or diastolic BP=70 and <110 mmHg Exclusion Criteria: - Allergic to organic nitrite, isoquercetin, niacin, or vitamin C - Institutionalized (e.g., prisoner, nursing home or skilled nursing facility resident) - Unable or unwilling to give consent - Known HIV infection and/or AIDS - Pregnant or lactating women - Currently on dialysis - Previous or current organ or bone marrow transplant - Receiving immunosuppressive treatment or other immunotherapy - Receiving chemotherapy or alkylating agents for systemic cancer - Recent acute myocardial infarction, cerebrovascular accidence or transient ischemic attack, or hospitalization in 3 months - Acute kidney injury within the previous 3 months - Currently taking a phosphodiesterase-5 enzyme inhibitor, such as Viagra - History of chronic headaches - Chronically receiving fluoroguinolones, cyclosporin (neural, sandimmune), nitrate drug, NSAIDS ( except aspirin = 81 mg daily), allopurinol or uloric, meperidine and related central nervous system (CNS) depressants, oral glucocorticoids, and not willing or able to stop during study period. - Active infection (i.e. systemic or osteomyelitis) - Class III or IV heart failure - History of hemolytic anemia including sickle cell disease - Hemoglobin <10 - History of chronic obstructive pulmonary disease (COPD) - Have a positive screen for glucose-6-phosphate dehydrogenase (G6PD) deficiency at screening - Involvement in other clinical trials - Current alcohol or other substance abuse - Current smokers - Unwillingness to stop flavonoid supplementation - Unwillingness to stop nitrate and/or nitrite supplementation

Study Design


Intervention

Drug:
Immediate release sodium nitrite
Immediate release sodium nitrite 40 mg by mouth twice per day
Dietary Supplement:
Isoquercetin
Isoquercetin 225 mg by mouth once per day
Other:
placebos
placebos

Locations

Country Name City State
United States Tulane School of Medicine New Orleans Louisiana

Sponsors (2)

Lead Sponsor Collaborator
Tulane University National Institute of General Medical Sciences (NIGMS)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Mean Percentage Change in Methemoglobin Over 12 Weeks A blood sample was drawn for each participant to measure the levels of methemoglobin. The mean percentage change between baseline, 6 weeks and 12 weeks in methemoglobin with 95% CI was calculated using linear mixed effects model. Baseline, 6 weeks, 12 weeks
Other Mean Change in Isoquercetin Over 12 Weeks A blood sample was drawn for each participant to measure the levels of isoquercetin. The mean changes between baseline, 6 weeks and 12 weeks in isoquercetin with 95% CI were calculated using linear mixed effects model. Baseline, 6 weeks, 12 weeks
Other Mean Change in Plasma Nitrite Over 12 Weeks A blood sample was drawn for each participant to measure the levels of plasma nitrite. The mean changes between baseline, 6 weeks and 12 weeks in plasma nitrite with 95% CI were calculated using linear mixed effects model. Baseline, 6 weeks, 12 weeks
Other Mean Change in Estimated-Glomerular Filtration Rate (eGFR) Over 12 Weeks Estimated-Glomerular Filtration Rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration equation. The equation is GFR = 141 * min(Scr/?,1)a * max(Scr/?, 1)-1.209 * 0.993Age * 1.018 [if female] * 1.159 [if black]. Scr is serum creatinine (mg/dL), ? is 0.7 for females and 0.9 for males, a is -0.329 for females and -0.411 for males, min indicates the minimum of Scr/? or 1, and max indicates the maximum of Scr/? or 1. The mean changes between baseline, 6 weeks and 12 weeks in eGFR with 95% CI were calculated using linear mixed effects model. Baseline, 6 weeks, 12 weeks
Other Mean Change in Lipid Profile Biomarkers Total Cholesterol, Low Density Lipoprotein (LDL)-Cholesterol and High Density Lipoprotein (HDL)-Cholesterol Over 12 Weeks A blood sample was drawn for each participant to measure the levels of total cholesterol, Low Density Lipoprotein (LDL)-cholesterol and High Density Lipoprotein (HDL)-cholesterol. The mean changes between baseline and 12 weeks in total cholesterol, Low Density Lipoprotein (LDL)-cholesterol and High Density Lipoprotein (HDL)-cholesterol with 95% CI were calculated using linear mixed effects model. Baseline,12 weeks
Other Mean Change in Lipid Profile Biomarker Triglycerides Over 12 Weeks A blood sample was drawn for each participant to measure the levels of triglycerides. The mean changes between baseline and 12 weeks in triglycerides with 95% CI were calculated using linear mixed effects model, and the log transformed triglyceride was calculated. Baseline,12 weeks
Other Mean Change in Hemoglobin Over 12 Weeks A blood sample was drawn for each participant to measure the levels of hemoglobin. The mean changes between baseline, 6 weeks and 12 weeks in hemoglobin with 95% CI were calculated using linear mixed effects model. baseline, 6 weeks, 12 weeks
Other Mean Change in Plasma Nitrate Over 12 Weeks A blood sample was drawn for each participant to measure the levels of plasma nitrate. The mean changes between baseline, 6 weeks and 12 weeks in plasma nitrate with 95% CI were calculated using linear mixed effects model. Baseline, 6 weeks, 12 weeks
Other Mean Change in Urinary Albumin-to-creatinine Ratios Over 12 Weeks A urine sample was taken for each participant to measure the levels of urinary albumin-to-creatinine ratios. The mean changes between baseline, 6 weeks and 12 weeks in urinary albumin-to-creatinine ratios with 95% CI were calculated using linear mixed effects model, and the log transformed urinary albumin-to-creatinine ratios was calculated. Baseline, 6 weeks, 12 weeks
Other Mean Change in Blood Pressure Over 12 Weeks Blood pressure was measured using the OMRON HEM-907 XL BP Monitor per standard protocol by trained and certified research staff. The mean changes between baseline, 6 weeks and 12 weeks in blood pressure with 95% CI were calculated using linear mixed effects model. Baseline, 6 weeks, 12 weeks
Other Mean Change in Pulse Over 12 Weeks Pulse was measured at the brachial artery per standard protocol by trained and certified research staff. The mean changes between baseline, 6 weeks and 12 weeks in pulse with 95% CI were calculated using linear mixed effects model. Baseline, 6 weeks, 12 weeks
Primary Mean Percentage Change in Endothelium-dependent Flow-mediated Vasodilation (FMD) Over 12 Weeks FMD was measured using high resolution ultrasound on the brachial artery. FMD was calculated as the maximal percentage change in vessel size during hyperemia . The mean changes between baseline, 6 weeks and 12 weeks in FMD with 95% CI were calculated using linear mixed effects model. Baseline, 6 weeks, 12 weeks
Secondary Mean Change in Endothelial Function Biomarkers VCAM-1, ICAM-1, E-selectin and vWF Over 12 Weeks A blood sample was drawn for each participant to measure the levels of Vascular Adhesion Molecule-1(VCAM-1), Intercellular Adhesion Molecule-1 (ICAM-1), E-selectin, and von Willebrand Factor (vWF). The mean changes between baseline, 6 weeks and 12 weeks in VCAM-1, ICAM-1, E-selectin and vWF with 95% CI were calculated using linear mixed effects model. Baseline, 6 weeks, 12 weeks
Secondary Mean Change in Endothelial Function Biomarker Asymmetrical DiMethylArginine (ADMA) Over 12 Weeks A blood sample was drawn for each participant to measure the levels of Asymmetrical DiMethylArginine (ADMA). The mean changes between baseline, 6 weeks and 12 weeks in ADMA with 95% CI were calculated using linear mixed effects model. Baseline, 6 weeks, 12 weeks
Secondary Mean Change in Endothelial Function Biomarker Endostatin Over 12 Weeks A blood sample was drawn for each participant to measure the levels of endostatin. The mean changes between baseline, 6 weeks and 12 weeks in endostatin with 95% CI were calculated using linear mixed effects model, and the log transformed endostatin was calculated. Baseline, 6 weeks, 12 weeks
Secondary Mean Change in Endothelial Function Biomarker Urine Epidermal Growth Factor (UEGF) Over 12 Weeks A urine sample was taken for each participant to measure the levels of Urine Epidermal Growth Factor (UEGF). The mean changes between baseline, 6 weeks and 12 weeks in UEGF with 95% CI were calculated using linear mixed effects model, and the log transformed Urine EGF/creatinine ratio was calculated. Baseline, 6 weeks, 12 weeks
Secondary Mean Change in Inflammatory Biomarker C-Reactive Protein (CRP) Over 12 Weeks A blood sample was drawn for each participant to measure the levels of C-Reactive Protein (CRP). The mean changes between baseline, 6 weeks and 12 weeks in CRP with 95% CI were calculated using linear mixed effects model. Baseline, 6 weeks, 12 weeks
Secondary Mean Change in Inflammatory Biomarkers Tumor Necrosis Factor-a (TNF-a), Interleukin-17 (IL-17), Interleukin-1ß (IL-1beta), and Monocyte Chemoattractant Protein-1 (MCP-1) Over 12 Weeks A blood sample was drawn for each participant to measure the levels of Tumor Necrosis Factor-a (TNF-a), interleukin-17 (IL-17), interleukin-1ß (IL-1beta), and Monocyte Chemoattractant Protein-1 (MCP-1). The mean changes between baseline, 6 weeks and 12 weeks in TNF-a, IL-17, IL-1beta, MCP-1 with 95% CI were calculated using linear mixed effects model. Baseline, 6 weeks, 12 weeks
Secondary Mean Change in Inflammatory Biomarker Interleukin-6 (IL-6) Over 12 Weeks A blood sample was drawn for each participant to measure the levels of interleukin-6 (IL-6). The mean changes between baseline, 6 weeks and 12 weeks in interleukin-6 (IL-6) with 95% CI were calculated using linear mixed effects model, and the log transformed IL-6 was calculated. Baseline, 6 weeks, 12 weeks
Secondary Mean Change in Oxidative Stress Biomarker Low-density Lipoprotein (LDL) Over 12 Weeks A blood sample was drawn for each participant to measure the levels of low-density lipoprotein (LDL). The mean changes between baseline, 6 weeks and 12 weeks in LDL with 95% CI were calculated using linear mixed effects model. Baseline, 6 weeks, 12 weeks
Secondary Mean Change in Oxidative Stress Biomarker Nitrotyrosine Over 12 Weeks A blood sample was drawn for each participant to measure the levels of nitrotyrosine. The mean changes between baseline, 6 weeks and 12 weeks in nitrotyrosine with 95% CI were calculated using linear mixed effects model. Baseline, 6 weeks, 12 weeks
See also
  Status Clinical Trial Phase
Completed NCT05491642 - A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses Phase 1
Recruiting NCT06363097 - Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
Terminated NCT04043026 - The Effects of Renal Function and Atrial Fibrillation on Lipoproteins and Clot Structure/Function
Completed NCT05318014 - Low-protein Formula Supplements in Chronic Kidney Disease N/A
Active, not recruiting NCT06071065 - Clinical Pharmacist Intervention on Medication Adherence and Clinical Outcomes in Chronic Kidney Disease Patients N/A
Completed NCT02878317 - Skin Autofluorescence as a Risk Marker in People Receiving Dialysis.
Not yet recruiting NCT06039254 - Safety and Pharmacokinetics of HRS-1780 in Healthy Subjects and Subjects With Impaired Renal Function Phase 1
Recruiting NCT03160326 - The QUALITY Vets Project: Muscle Quality and Kidney Disease
Completed NCT02756520 - Observational Study on CKD Treatment With a Ketosteril Supplemented Protein-restricted Diet (Keto-024-CNI)
Completed NCT02896309 - The Effect of Correction of Metabolic Acidosis in CKD on Intrarenal RAS Activity N/A
Withdrawn NCT02885545 - The Strategy to Prevent Hemorrhage Associated With Anticoagulation in Renal Disease Management (STOP HARM) Trial Phase 4
Completed NCT02836574 - A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease Phase 2
Completed NCT02875886 - DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease Phase 4
Completed NCT02888171 - Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency N/A
Active, not recruiting NCT02483039 - Nephrologist Follow-up Versus Usual Care After an Acute Kidney Injury Hospitalization N/A
Completed NCT02369549 - Micro-Particle Curcumin for the Treatment of Chronic Kidney Disease Phase 3
Completed NCT02992548 - Effect of Pravastatin on Erythrocyte Membrane Fatty Acid Contents in Patients With Chronic Kidney Disease Phase 4
Terminated NCT02543177 - Optimised Procedure in Patients With NSTEMI and CKD N/A
Recruiting NCT02205944 - Impact of Presurgical Exercise on Hemodialysis Fistula Outcomes N/A
Active, not recruiting NCT02231138 - Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease Phase 4